It is 'kind of a proven tech­nol­o­gy': Hep B vac­cine mak­er joins glob­al hunt for coro­n­avirus vac­cine

6 years ago
R&D
Coronavirus

My­ovant grabs $40M up­front in re­gion­al deal for re­l­u­golix; Akero an­nounces NASH suc­cess but Covid-19 de­lays

6 years ago
News Briefing

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

6 years ago
FDA+

Just in time to as­sure a de­ci­sion be­fore CVR dead­line, Bris­tol My­ers Squibb files NDA for Cel­gene/blue­bird CAR-T

6 years ago
R&D

Can a pair of top AveX­is alum­ni steer a new gene ther­a­py up­start to R&D glo­ry? 3 VCs bet $60M on it

6 years ago
Financing
R&D

Brii Bio gets all hands on deck for Covid-19 an­ti­body hunt, lever­ag­ing Chi­nese part­ner­s' work with re­cov­ered pa­tients

6 years ago
R&D
China

Un­de­terred by a pan­dem­ic, Gilde Health­care rais­es their largest fund yet

6 years ago
Financing

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic ...

6 years ago
Coronavirus

Eli Lil­ly antes up $60M gam­ble on a dis­cov­ery deal with GSK-backed biotech

6 years ago
Deals

Un­fazed by dis­rup­tions, Cowen's in­vest­ment arm backs AM-Phar­ma's $176M piv­otal plan around lethal con­di­tion

6 years ago
Financing

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

6 years ago
R&D

Covid-19 and weak da­ta force pipeline re­vamp at Rea­ta, but the best tri­als go for­ward — with some cre­ative ...

6 years ago
R&D
Coronavirus

As­traZeneca ex­pands deal with Imag­inAb; Ovid posts promis­ing da­ta on Take­da-part­nered seizure drug

6 years ago
News Briefing

David Hal­lal bags an­oth­er whop­per round, look­ing to re­cruit more cell and gene ther­a­py up­starts to El­e­vate­Bio ...

6 years ago
Financing
Startups

New­ly-pub­lic Im­muno­vant an­nounces first proof-of-con­cept suc­cess

6 years ago
R&D

Lund­beck adds a Parkin­son's flop to its list of set­backs, writ­ing off a $1.1 bil­lion deal on mid-stage fail­ure

6 years ago
R&D

Ax­some re­ports late-stage de­pres­sion tri­al de­feat, shares wilt

6 years ago
R&D

Covid-19 roundup: J&J, BAR­DA set ear­ly 2021 fin­ish line for $1B vac­cine race; FDA al­lows emer­gency drug use, ahead of ...

6 years ago
Coronavirus

Mer­ck and Bay­er un­veil the da­ta be­hind their CV ‘suc­cess,’ un­der­whelm­ing the in­dus­try

6 years ago
R&D

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

6 years ago
R&D
Pharma

As­traZeneca gets a green light on Imfinzi for small-cell lung can­cer — set­ting the stage for a bat­tle with Roche's ...

6 years ago
Pharma
FDA+

IL-6 to the res­cue? Sanofi, Re­gen­eron bar­rel ahead in­to an­oth­er piv­otal ef­fort test­ing Kevzara for Covid-19

6 years ago
Deals
Coronavirus

Gilead CEO Dan O'­Day of­fers a de­tailed ex­pla­na­tion on remde­sivir ac­cess — re­as­sur­ing an­a­lysts that Covid-19 da­ta ...

6 years ago
R&D
Coronavirus

As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

6 years ago
R&D
Coronavirus
First page Previous page 840841842843844845846 Next page Last page
A service from the Financial Times